Pharma On Its Back Foot As US Drug Price Reform Advances
Executive Summary
Big pharma leaders warn of steep cuts to R&D and US jobs if US drug pricing reform legislation paves the way for direct government price negotiations.
You may also be interested in...
Part B Is Plan B: Specialty Drug Prices Primed For Fallback Reform Effort
As Biden administration and MedPAC both work on ideas to overhaul Part B, marketers of physician-administered drugs (primarily for cancer, ophthalmology and rheumatological disorders) should prepare for a fight – but only if the broader ‘negotiation’ push fails.
Under The Shadow Of Drug Price Reform, US Tax Policies Still Challenge Pharma
Congress is considering legislation that would reverse some of the Trump administration's friendly corporate tax policies, presenting another challenge to the biopharmaceutical industry.
Generic Drugs: ‘Competitive’ Exclusivity Benefited Few Sponsors But Is Increasingly Popular
The six months of additional exclusivity from US FDA’s CGT program appears to have kept some generic sponsors from the market, and didn’t even prompt others to enter quickly, but use of the competitive generic exclusivity program continues to grow.